All In Biotech

Drug Trial Radar · NCT06449222

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer

Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

83

Actual

Start

Aug 26, 2024

Primary completion

Aug 2028

Study completion Jun 2029

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Jun 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).

Conditions

  • Locally Advanced Breast Cancer
  • Triple Negative Breast Cancer
  • Metastatic Triple Negative Breast Cancers

Interventions

  • BNT327 Dose Level 1 (DL1)Drug

    Intravenous (IV) infusion

  • BNT327 Dose Level 1 (DL2)Drug

    IV infusion

  • Nab-placlitaxelDrug

    IV infusion

  • CarboplatinDrug

    IV infusion

  • GemcitabineDrug

    IV infusion

  • PaclitaxelDrug

    IV infusion

  • EribulinDrug

    IV infusion

  • BNT327 Optimized DoseDrug

    IV infusion

  • BNT327 Equivalent Q3W DoseDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of treatment emergent adverse events (TEAEs), adverse events of special interest (AESIs), treatment emergent serious adverse events (SAEs)Time frame: up to 100 days after the last dose of treatment
  2. Occurrence of dose interruption, dose reduction, and discontinuation of study treatment due to adverse events (AEs)Time frame: up to 100 days after the last dose of treatment
  3. Objective Response Rate (ORR)Time frame: Until end-of-treatment visit, i.e., up to 24 months after the first dose of treatment
  4. Best percentage change from baseline in the tumor sizeTime frame: Until end-of-treatment visit, i.e., up to 24 months after the first dose of treatment
  5. Proportion of participants who have achieved early tumor shrinkageTime frame: up to 4 months after first dose of treatment

Locations

31 sites in 4 countries. Site status is shown where the registry gives one.

  • Beverly Hills Cancer Center

    Beverly Hills, California

  • Valkyrie Clinical Trials

    Los Angeles, California

  • Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center

    Palo Alto, California

  • Saint John's Health Center - John Wayne Cancer Institute (JWCI)

    Santa Monica, California

  • Rocky Mountain Cancer Centers (RMCC)

    Denver, Colorado

  • Yale University - Yale Cancer Center

    New Haven, Connecticut

  • Carle Foundation Hospital d/b/a Carle Cancer Center

    Urbana, Illinois

  • HealthPartners Regions Specialty Clinics

    Saint Louis Park, Minnesota

  • Rutgers Cancer Institute of NJ (Rutgers, The State University of New Jersey)

    New Brunswick, New Jersey

  • Stony Brook University Hospital

    Stony Brook, New York

  • The West Clinic, P.C. d/b/a West Cancer Center

    Germantown, Tennessee

  • SCRI Oncology Partners

    Nashville, Tennessee

  • Bon Secours St. Francis Medical Center

    Midlothian, Virginia

  • Peninsula Oncology Centre

    Frankston, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Australia

  • Baskent Universitesi Tip Fakultesi Adana Hastanesi

    Adana, Turkey (Türkiye)

  • Medical Park Seyhan Hospital

    Adana, Turkey (Türkiye)

  • Sakarya University - Faculty of Medicine

    Adapazarı, Turkey (Türkiye)

  • Hacettepe Universitesi Kanser Enstitusu

    Ankara, Turkey (Türkiye)

  • Sbu Dr.A.Y. Ankara Onkoloji SUAM

    Ankara, Turkey (Türkiye)

  • Memorial Ankara Hospital

    Ankara, Turkey (Türkiye)

  • Koc Universitesi Hastanesi (Koc University Hospital)

    Istanbul, Turkey (Türkiye)

  • Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi

    Istanbul, Turkey (Türkiye)

  • Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi

    Istanbul, Turkey (Türkiye)

  • Yeditepe University Hospital

    Istanbul, Turkey (Türkiye)

  • Hull and East Yorkshire Hospitals NHS Trust - Castle Hill Hospital

    Cottingham, United Kingdom

  • Edinburgh Cancer Centre-Western General Hospital

    Edinburgh, United Kingdom

  • St James's University Hospital - Leeds Teaching Hospitals NHS Trust

    Leeds, United Kingdom

  • St Bartholomew's Hospital - Barts Health NHS Trust

    London, United Kingdom

  • Sarah Cannon Research Institute

    London, United Kingdom

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.